McWherter Charles

Director McWherter bought 15,000 shares at $6.55-$6.71 (blended $6.66) on Jan 21-22; holds 25,000 post-transaction.

Director Charles McWherter made 2 separate purchases totaling 15,000 shares for $99,850.00 over January 21-22, increasing his stake by 150.0% from 10,000 to 25,000 shares. The purchases at $6.55–$6.71 occurred as the stock trades 49.8% below its 52-week high of $13.77, and the company reported a negative net income of $-149,073,000.00 for its most recent full fiscal year. His single prior open-market buy at ETNB (December 5, 2024) showed a 30-day return of -0.5%, and his cross-ticker track record across all holdings shows 1 prior buy with an average 30-day return of -0.5%, establishing a pattern without measurable success in recent timing. The purchase into an unprofitable, declining-price environment warrants scrutiny of whether this reflects access to non-public information or represents a discretionary conviction call in a challenging fundamental backdrop.

ETNB Director McWherter purchases 10,000 shares at $8.00; stock down 41.7% from 52-week high amid $-149.1M annual loss.

Charles McWherter, a director of 89bio, initiated a first position in the company by purchasing 10,000 shares at $8.00 on 2024-12-05, investing $80,000.00 total. The transaction occurs against a backdrop of significant operational challenges: the company posted a net income of $-149,073,000.00 over its most recent full fiscal year and the stock has declined 41.7% from its 52-week high of $13.77, trading near the lower end of its annual range at $8.03. The purchase follows a steep 30-day decline of 23.2%, suggesting the director acquired shares after a recent selloff. With the company unprofitable and the stock under pressure, this transaction reflects a substantial commitment by a board member at a depressed valuation point, though the company's loss-making status limits confidence in near-term inflection.